\n\n
Key developments: OpenAI has quietly added a new life‑sciences model, gpt‑rosalind‑discovery, to its API pricing page, positioning it as a dedicated drug‑discovery tool. The model appears beside the existing gpt‑rosalind‑research offering and is priced the same, suggesting a strategic focus on pharma customers rather than immediate profit. This follows the branding of the Rosalind platform—named after DNA pioneer Rosalind Franklin—and reflects OpenAI’s shift toward vertical industry solutions.
Why it matters: The introduction of a specialized discovery model underscores the growing commercial appetite for AI in early‑stage drug design, a sector where investment has more than doubled to $8.4 billion in 2025 (McKinsey). AI‑driven virtual trial platforms, such as BioinvestGPT, are already proving their predictive value—accurately forecasting a failed late‑stage trial for Novartis’s del‑desiran—demonstrating how simulation can de‑risk expensive clinical programs. As the industry spends roughly $140 billion annually on human trials with a modest 12% success rate, tools that can “run fewer trials that are going to fail” are becoming essential.
What to watch next:
- How OpenAI’s gpt‑rosalind‑discovery performs in real pharma collaborations and whether pricing or access differentiates it from the research‑focused counterpart.
- Adoption rates of virtual trial simulators across major drug makers and potential regulatory pathways that could formalize AI predictions in trial design.
- Continued capital inflows into AI drug discovery and the balance between open‑data initiatives and proprietary pharma datasets that will shape model accuracy. [[1, 2]]